Search

Your search keyword '"Gimenez-Arnau, Ana"' showing total 134 results

Search Constraints

Start Over You searched for: Author "Gimenez-Arnau, Ana" Remove constraint Author: "Gimenez-Arnau, Ana" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
134 results on '"Gimenez-Arnau, Ana"'

Search Results

3. Occupational Contact Urticaria Syndrome

6. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

9. Drug Photosensitivity

10. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

13. Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment—Results From CURE

14. Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study

15. Urticarial Vasculitis Differs From Chronic Spontaneous Urticaria in Time to Diagnosis, Clinical Presentation, and Need for Anti-Inflammatory Treatment: An International Prospective UCARE Study

16. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results

17. Contact Dermatitis: Overcoming Challenges of Specific Patients, Deciphering the Results and Reaching a Correct Diagnosis

20. Biological drugs for the treatment of children with chronic spontaneous urticaria.

22. Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015)

23. Enhancing Angioedema Patient Care: Unveiling Underutilization and Barriers in the Implementation of Patient-Reported Outcome Measurements

25. Efficacy of Remibrutinib in Patients With Chronic Spontaneous Urticaria With or Without Prior Exposure to Biologics in the Phase 3 REMIX-1 and REMIX-2 Studies

27. Time to Relapse During Treatment-Free Follow-Up Without Remibrutinib in Patients With Chronic Spontaneous Urticaria: Subgroup Analysis By Baseline Immunoglobulin-E Levels and Chronic Urticaria Index Status From a Phase 2b Extension Study

28. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

29. CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

30. CRUSE®-An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

31. 156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis

32. CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

33. Emerging Systemic Treatment Options in Atopic Dermatitis.

34. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

35. Usage prevalence of angioedema patient–reported outcome measures: Results from the UCARE and ACARE PROMUSE study

36. Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: An international Delphi survey

37. Efficacy and safety of on‐demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial

38. Alexithymia prevalence in individuals with chronic urticaria and its association with illness severity and therapeutic profile

39. In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria

40. CRUSE – What the first 100 days have taught us

41. A concept for integrated care pathways for atopic dermatitis- a GA2LEN ADCARE initiative

42. Occupational contact allergy: The European perspective-Analysis of patch test data from ESSCA between 2011 and 2020

43. Treatment patterns and outcomes in patients with chronic urticaria during pregnancy: results of PREG-CU, a UCARE study

44. Efficacy and safety of on‐demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial.

46. CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria.

48. Occupational contact allergy: The European perspective - analysis of patch test data from ESSCA between 2011-2020

49. Occupational contact allergy: The European perspective–Analysis of patch test data from ESSCA between 2011 and 2020

50. Total IgE levels are linked to the course of chronic spontaneous urticaria during pregnancy

Catalog

Books, media, physical & digital resources